Bicycle Therapeutics

Overview

Clinical-stage biotech using phage display-derived bicyclic peptides as targeting vehicles for radiopharmaceutical payloads, including lead-212 targeted alpha therapy. Bicycle Therapeutics uses phage display technology to produce bicyclic peptides that target proteins overexpressed on cancer cells, delivering a variety of payloads including radioisotopes that are internalized and destroy the cancer cell. Bicycle Therapeutics operates without the tens of billions of dollars Novartis invested in radiopharmaceutical supply chain infrastructure, and instead relies on a network of CDMOs and creative upstream sourcing agreements to bring products to patients. (Segment 4 (15:00-20:00))